Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Willett, CG; Boucher, Y; Duda, DG; di Tomaso, E; Munn, LL; Tong, RT; Kozin, SV; Petit, L; Jain, RK; Chung, DC; Sahani, DV; Kalva, SP; Cohen, KS; Scadden, DT; Fischman, AJ; Clark, JW; Ryan, DP; Zhu, AX; Blaszkowsky, LS; Shellito, PC; Mino-Kenudson, M; Lauwers, GY

Published Date

  • November 1, 2005

Published In

Volume / Issue

  • 23 / 31

Start / End Page

  • 8136 - 8139

PubMed ID

  • 16258121

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.02.5635


  • eng

Conference Location

  • United States